Multiple Myeloma Coverage from Every Angle

Taiga Nishihori, MD: Is Maintenance Ixazomab Feasible in High-Risk Myeloma?

Posted: Friday, June 4, 2021

Taiga Nishihori, MD, of the H. Lee Moffitt Cancer Center and Research Institute, talks about why a study of maintenance ixazomab after transplant in patients with high-risk myeloma had to be suspended, and the lessons learned in preventing or reducing toxicities in this setting.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.